Labcorp Holdings Non-GAAP EPS of $4.78 beats by $0.14, revenue of $3.81B beats by $50M, raises FY guidance
Labcorp Holdings beat expectations with a Non-GAAP EPS of $4.78, topping estimates by $0.14, and achieved revenue of $3.81B, exceeding forecasts by $50M, while raising its full-year (FY) guidance.
Along with strong news of solid earnings and upward guidance revision, the current stock price is located just below the resistance level ($332.34) and the RSI is in the overbought zone at 72.2. Therefore, entry will be considered with a strategy of either definitively confirming a breakout above the resistance level or targeting a pullback near the support level ($302.71).
Since the current share price is located just below the resistance level ($332.34), if it breaks through this resistance, I will respond around the take-profit target of $332.34. If the upward momentum falters and declines, I will manage risk by setting the stop-loss at the support level of $302.71.
At the time of entry, the technical indicators show an RSI(14) of 72.2, indicating an overbought zone. The moving averages are not in a bullish alignment, trading volume is 1.26 times the 20-day average, and the 7-day volatility (rate of change) stands at +4.2%.
예측 시점에는 RSI 72.2의 과매수 구간과 저항선($332.34) 바로 아래에 위치한 주가 때문에 신중하게 저항선 돌파나 지지선($302.71) 눌림목을 노리려 했으나, 실제 결과는 예상보다 훨씬 강한 상승세를 보이며 11.2%의 수익률(OVERHIT)을 기록했다. 실적 호조와 가이던스 상향이라는 강력한 촉매제와 테마 내 뉴스 증가세(최근 7일 77건)가 맞물려, 과매수 구간임에도 불구하고 매수세가 강하게 유입된 점을 충분히 반영하지 못하고 보수적으로만 접근했던 점이 아쉬운 대목이다.
For stocks that will feature strong earnings surprises accompanied by upward guidance, if the RSI is in an overbought range but is supported by the overall theme momentum (rising trend and S-Class conversion rate) and trading volume (1.26 times the 20-day average), I will actively consider a strategy of expanding position size in a trend-following perspective when the resistance line is broken.